🇺🇸 RCUS — Arcus Biosciences, Inc.

Salud Compra fuerte
← Volver

Precio actual

19,31 USD

Máx. histórico

48,47

1807 días

Caída desde máximo

-60,16%

Rango 52 semanas

17,43 – 31,74

Variación hoy

+2,12%

Cierre anterior

18,91

Rango de hoy

18,60 – 19,61

Volumen hoy

2.076.185

Peor caída histórica

-85,83%

23/11/2021 → 04/04/2025

Aún sin recuperar

Volatilidad anualizada ⓘ

75,61%

Información
Nombre completo
Arcus Biosciences, Inc.
Divisa
USD
Mercado
NYSE
Sector
Salud
Industria
Biotechnology
Empleados
601
PER ⓘ
—
Dividend yield
0,00% (puede no estar actualizado)
Precio objetivo analistas
41,00 USD (puede no estar actualizado)
Primera cotización
15/03/2018
Precio actualizado
hace 14 horas
Sobre la empresa

Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's development product portfolio includes Casdatifan, a HIF-2a inhibitor for the treatment of kidney cancer; Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial for lung and gastrointestinal cancers; and Zimberelimab, an anti-PD-1 antibody. It also develops Quemliclustat, a small molecule inhibitor that targets the CD73 enzyme in the ATP-adenosine pathway, which is in phase 3 and phase 1/1b clinical trial for lung and pancreatic cancer. In addition, the company develops AB598, a CD39 antibody, which is in phase 1/1b clinical study for gastrointestinal cancer and AB801, an AXL inhibitor, which is in Phase 1b clinical trial for lung cancer. It has clinical collaboration with AstraZeneca for the Phase 3 PACIFIC-8 trial evaluating domvanalimab and durvalumab in Stage 3 NSCLC and for a Phase 1/1b study evaluating casdatifan and volrustomig in IO-naive patients with ccRCC; BVF Partners L.P. to support the discovery and development of compounds for the treatment of inflammatory diseases; and Bristol-Myers Squibb Company to develop a novel treatment regimen that delivers tumor control in kidney cancer. Arcus Biosciences, Inc. was incorporated in 2015 and is based in Hayward, California.

Rentabilidad mensual
Evolución
Histórico día a día
Fecha Apertura Máximo Mínimo Cierre Variación Volatilidad día Volumen
20/04/2022 31,36 31,53 30,55 31,25 -0,26% 3,14% 525.800
19/04/2022 31,34 32,37 30,69 31,33 +0,35% 5,36% 555.500
18/04/2022 32,05 32,30 30,97 31,22 -2,38% 4,13% 538.000
14/04/2022 31,61 32,02 30,67 31,98 +0,35% 4,27% 678.200
13/04/2022 30,80 32,68 30,80 31,87 +3,64% 6,10% 634.500
12/04/2022 31,71 32,03 30,32 30,75 -1,91% 5,38% 845.800
11/04/2022 33,23 33,59 31,10 31,35 -6,97% 7,49% 991.400
08/04/2022 33,96 35,03 33,51 33,70 -1,09% 4,48% 1.252.000
07/04/2022 34,19 35,65 33,00 34,07 -2,96% 7,75% 1.349.200
06/04/2022 37,23 37,65 34,16 35,11 -6,94% 9,37% 13.084.900
05/04/2022 39,13 39,75 36,50 37,73 +8,14% 8,31% 7.623.100
04/04/2022 32,35 35,36 32,28 34,89 +9,07% 9,52% 964.800
01/04/2022 31,62 33,12 31,47 31,99 +1,36% 5,20% 731.300
31/03/2022 33,37 33,82 31,26 31,56 -5,51% 7,67% 1.298.500
30/03/2022 36,51 36,51 33,36 33,40 -9,73% 8,64% 1.397.900
29/03/2022 36,74 37,46 36,61 37,00 +1,37% 2,31% 947.500
28/03/2022 35,95 37,44 35,64 36,50 +1,50% 5,01% 577.500
25/03/2022 34,77 36,48 34,49 35,96 +3,57% 5,72% 757.600
24/03/2022 33,49 34,84 32,84 34,72 +5,28% 5,97% 778.500
23/03/2022 33,99 34,46 32,96 32,98 -4,38% 4,41% 620.300
22/03/2022 34,82 35,41 34,02 34,49 -0,38% 3,99% 606.600
21/03/2022 35,42 36,12 34,17 34,62 -3,70% 5,51% 545.900
18/03/2022 34,50 36,44 33,88 35,95 +4,20% 7,42% 1.421.400
17/03/2022 32,87 34,50 32,63 34,50 +3,39% 5,69% 430.200
16/03/2022 31,62 33,42 31,48 33,37 +5,43% 6,14% 555.300
15/03/2022 31,18 31,69 30,47 31,65 +0,99% 3,92% 297.700
14/03/2022 33,06 33,11 30,83 31,34 -5,32% 6,91% 554.800
11/03/2022 34,50 34,60 33,05 33,10 -4,17% 4,49% 295.600
10/03/2022 34,21 34,76 33,46 34,54 +0,06% 3,80% 360.200
09/03/2022 33,65 34,73 33,51 34,52 +4,51% 3,63% 471.300